BioCentury | Apr 23, 2020

Crossovers back Affinivax in $120M series B to broaden clinical vaccine pipeline

Though it once felt it could do without a large cash infusion from VCs, Affinivax has chosen to raise $120 million in a series B round that is designed to advance a handful of preclinical...
BC Innovations | Dec 5, 2019
Emerging Company Profile

VaxNewMo: bioconjugating antibacterial vaccines

VaxNewMo is developing a bioengineered platform that could yield inexpensive glyconjugate vaccines that prevent bacterial infections, including those not yet covered by existing vaccines. Traditional chemical glycoconjugation is laborious and expensive, as it typically involves...
Items per page:
1 - 2 of 2